Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Lee Jackson | Aug 4, 2015 at 8:35 AM EDT

3 Potential Huge Takeover Targets in Biotech

In a new research report, Cowen's well-respected analyst Ken Cacciatore makes a very good case that some huge, high-profile biotech…

Chris Lange | Aug 3, 2015 at 11:25 AM EDT

Independent Research Firm Sees Higher Upside in Amgen

According to Argus, second-quarter earnings, along with a strong pipeline and general outlook, have positioned Amgen to take the market…

Chris Lange | Aug 3, 2015 at 11:05 AM EDT

Positive Developments Around Ebola

Ebola fears have subsided and the development of a vaccine or related drugs has been put on the back burner…

Lee Jackson | Aug 3, 2015 at 10:40 AM EDT

3 Biotech Stocks to Buy With Huge Catalysts Coming Soon

SunTrust Robinson Humphrey handicaps some of the upcoming events for stocks in the firm's coverage universe that have potential market-moving…

Chris Lange | Aug 3, 2015 at 10:15 AM EDT

INC Research Files for Secondary Offering

INC Research Holdings has filed with the Securities and Exchange Commission (SEC) for a secondary offering.

Chris Lange | Aug 3, 2015 at 10:05 AM EDT

Zynerba Updates IPO Terms

Zynerba Pharmaceuticals has amended its filing with the Securities and Exchange Commission (SEC) for its initial public offering

Jon C. Ogg | Jul 31, 2015 at 1:44 PM EDT

Teva Proves Its Decade-Hold Status With Massive Funding

ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday…

Chris Lange | Jul 31, 2015 at 10:10 AM EDT

Global Blood Therapeutics Updates Terms in IPO

ThinkstockGlobal Blood Therapeutics Inc. filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial…

Paul Ausick | Jul 30, 2015 at 4:26 PM EDT

Amgen Earnings Point to New 52-Week High

ThinkstockAmgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm…

Chris Lange | Jul 30, 2015 at 3:52 PM EDT

Why Merrill Lynch Upgraded Aetna

ThinkstockMerrill Lynch upgraded Aetna Inc. (NYSE: AET) to Buy from Neutral but maintains its price objective at $132, implying an…

Chris Lange | Jul 30, 2015 at 11:23 AM EDT

What to Expect from Amgen Earnings

ThinkstockAmgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates…

Chris Lange | Jul 30, 2015 at 9:13 AM EDT

Are Teva Earnings Enough?

ThinkstockTeva Pharmaceutical Industries Limited (NYSE: TEVA) reported its second-quarter financial results Thursday before the markets opened. The company had $1.43…

Douglas A. McIntyre | Jul 30, 2015 at 5:48 AM EDT

More Doctors Flee Private Practice

ThinkstockThe old style independent doctor has continued to disappear. Practicing in a hospital has become a better financial deal, as…

Chris Lange | Jul 29, 2015 at 5:09 PM EDT

Is This a Turning Point For Unilife?

ThinkstockUnilife Corp. (NASDAQ: UNIS) announced the introduction of the Imperium platform of instant patch pumps for insulin. The platform is…

Chris Lange | Jul 29, 2015 at 1:27 PM EDT

Should Gilead Really Be Rated Underperform?

ThinkstockMost analysts seem to be behind the growth that Gilead Sciences Inc. (NASDAQ: GILD) has seen, namely in its Hepatitis…

1 … 252 253 254 255 256 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

3 Potential Huge Takeover Targets in Biotech

Independent Research Firm Sees Higher Upside in Amgen

Positive Developments Around Ebola

3 Biotech Stocks to Buy With Huge Catalysts Coming Soon

INC Research Files for Secondary Offering

Zynerba Updates IPO Terms

Teva Proves Its Decade-Hold Status With Massive Funding

Global Blood Therapeutics Updates Terms in IPO

Amgen Earnings Point to New 52-Week High

Why Merrill Lynch Upgraded Aetna

What to Expect from Amgen Earnings

Are Teva Earnings Enough?

More Doctors Flee Private Practice

Is This a Turning Point For Unilife?

Should Gilead Really Be Rated Underperform?

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

After Comparing Every Weekly Pay ETF on the Market, Roundhill’s Lineup Is the Only One Somewhat Delivering

Why $34,000 Is the Social Security Tax Threshold Most Retirees Never See Coming

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

Why $34,000 Is the Social Security Tax Threshold Most Retirees Never See Coming

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

After Comparing Every Weekly Pay ETF on the Market, Roundhill’s Lineup Is the Only One Somewhat Delivering

Health and Healthcare Articles

All Health and Healthcare Articles

3 Potential Huge Takeover Targets in Biotech

Independent Research Firm Sees Higher Upside in Amgen

Positive Developments Around Ebola

3 Biotech Stocks to Buy With Huge Catalysts Coming Soon

INC Research Files for Secondary Offering

Zynerba Updates IPO Terms

Teva Proves Its Decade-Hold Status With Massive Funding

Global Blood Therapeutics Updates Terms in IPO

Amgen Earnings Point to New 52-Week High

Why Merrill Lynch Upgraded Aetna

What to Expect from Amgen Earnings

Are Teva Earnings Enough?

More Doctors Flee Private Practice

Is This a Turning Point For Unilife?

Should Gilead Really Be Rated Underperform?

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

After Comparing Every Weekly Pay ETF on the Market, Roundhill’s Lineup Is the Only One Somewhat Delivering

Why $34,000 Is the Social Security Tax Threshold Most Retirees Never See Coming

Featured Reads

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

Why $34,000 Is the Social Security Tax Threshold Most Retirees Never See Coming